Spravato (esketamine) nasal spray received FDA approval in March 2019 for Treatment Resistant Depression Therapy.
What to Expect
Treatments are self-administered under the supervision of a licensed psychiatrist or nurse practitioner. Prospective patients should expect to come twice weekly for the first four weeks and once weekly for a minimum of an additional four weeks.
Each treatment session lasts approximately two hours during which the patient will self-administer the medication and be monitored for potential side effects.
Patients will be restricted from driving after treatment. It is advised they arrange for safe transportation to and from the appointment. Companions are welcome during the treatment procedure and we encourage you to bring support if possible. Be aware patients restricted from driving until the following day after a sound night’s rest.
If you have questions or wish to speak to a member of our Spravato Team call 262.241.8100.
To learn more about Spravato click here
Mequon Clinical Associates is continuing to see patients. *Update as of 5/13